HISUN(SH:600267)2017-04-27 16:00Financial Performance - Operating revenue for the first quarter reached CNY 2.74 billion, a year-on-year increase of 14.96%[6] - Net profit attributable to shareholders was CNY 6.83 million, reflecting a 12.50% increase from the same period last year[6] - Basic earnings per share rose by 16.67% to CNY 0.007 per share[8] - Total operating revenue for the current period reached ¥2,737,986,619.26, an increase of 15.0% compared to ¥2,381,670,475.84 in the previous period[28] - Net profit for the current period was ¥80,321,592.01, representing a 88.5% increase from ¥42,651,367.63 in the previous period[28] - The net profit attributable to the parent company's shareholders was ¥6,831,898.06, slightly up from ¥6,072,564.76 in the prior period[28] - The company reported a profit margin of approximately 2.93% for the current period, compared to 1.79% in the previous period[28] Cash Flow - Cash flow from operating activities surged by 320.24% to CNY 84.48 million compared to the previous year[6] - Cash flow from operating activities generated a net amount of ¥84,475,183.38, significantly higher than ¥20,101,889.75 in the previous period[34] - Total cash inflow from operating activities was ¥641,695,657.52, up from ¥585,842,626.75 year-over-year, indicating a growth of approximately 9.5%[37] - The net cash flow from operating activities for Q1 2017 was ¥34,537,969.94, a significant improvement compared to a net outflow of ¥2,208,249.20 in the same period last year[37] - The ending cash and cash equivalents balance was ¥1,131,111,972.64, down from ¥1,650,647,172.30 at the end of the previous year[38] - The total cash and cash equivalents decreased by ¥118,277,248.22 during the quarter, contrasting with an increase of ¥829,854,811.74 in the same quarter last year[38] Assets and Liabilities - Total assets increased by 1.81% to CNY 21.13 billion compared to the end of the previous year[6] - Current liabilities rose to CNY 7,560,083,839.92 from CNY 7,346,169,020.65, an increase of about 2.9%[22] - Total liabilities rose to CNY 13,014,576,285.52 from CNY 12,719,039,884.56, reflecting an increase of about 2.3%[22] - Owner's equity increased to CNY 8,119,178,320.29 from CNY 8,039,232,609.51, a growth of approximately 1.0%[22] - Non-current assets totaled CNY 13,861,171,319.21, up from CNY 13,537,129,354.46, reflecting a growth of approximately 2.4%[22] Shareholder Information - The total number of shareholders reached 31,600 by the end of the reporting period[10] - Zhejiang Haizheng Group Co., Ltd. held 33.22% of the shares, making it the largest shareholder[10] Investments and Financial Management - The company approved a financial assistance agreement with its controlling shareholder, allowing for up to ¥400 million in financial support, with an outstanding principal of ¥245 million as of the report date[13] - The company’s wholly-owned subsidiary, Haizheng Pharmaceutical (Hangzhou) Co., Ltd., received an investment of ¥177 million from the National Development Fund, acquiring a 3.99% equity stake[15] - The company completed the first phase of a capital increase of ¥280 million for its wholly-owned subsidiary, Haizheng Pharmaceutical Nantong Co., Ltd., increasing its registered capital to ¥310 million[17] - The company issued financial instruments for direct financing with a limit of up to ¥1 billion, having already issued ¥500 million[15] Operational Efficiency - Cash inflow from financing activities totaled ¥755,907,774.71, down from ¥1,580,421,390.11 in the previous year, representing a decline of approximately 52%[38] - The company recorded a decrease in financial expenses to ¥71,559,096.79 from ¥52,307,499.62 in the previous period, indicating increased financial management efficiency[28] - Sales expenses increased to ¥327,130,701.06, up from ¥260,566,109.49, reflecting higher marketing efforts[28] Inventory and Receivables - Accounts receivable increased by 28.60% to ¥1,643,130,285.43 from ¥1,277,700,700.88, primarily due to growth in revenue from formulations and third-party business[13] - Prepayments rose by 41.15% to ¥187,716,344.98 from ¥132,991,860.80, mainly due to increased advance payments for third-party business by a wholly-owned subsidiary[13] - Inventory decreased to ¥1,975,891,113.09 from ¥2,063,187,177.54, indicating a reduction in stock levels[20] - Accounts receivable increased to CNY 342,764,941.59 from CNY 322,358,542.14, showing a growth of approximately 6.3%[25] - Inventory decreased to CNY 606,940,402.76 from CNY 626,219,642.45, a decline of about 3.1%[25]